You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Motion-robust brain MRI for infants
SBC: TURING MEDICAL TECHNOLOGIES INC Topic: 101Project Abstract/Summary The objective of this SBIR/STTR Fast Track submission is to provide a software solution to reduce the effects of head motion during brain MRIs of infants. Because structural MRI scanning produces high-resolution images and does not expose patients to radiation, it has become an immensely valuable diagnostic tool, particularly for imaging the brain in infant samples. Approx ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Visual biofeedback to reduce head motion during MRI scans
SBC: TURING MEDICAL TECHNOLOGIES INC Topic: 101Project Abstract/Summary The goal of this STTR application is to deliver a brain MRI technology that feeds back head motion measurements derived from our Framewise Integrated Real-Time MRI Monitoring (FIRMM) to MRI scan participants in order to reduce head motion via behavioral training. Because MRI scanning produces high- resolution images and does not expose patients to radiation, it has become ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Clinical Vector for TCR Immunotherapy Targeted to Melanoma
SBC: LENTIGEN CORPORATION Topic: NCIDESCRIPTION (provided by applicant): This Phase II proposal is a continuation of our Phase I award, Lentiviral Vectors for TCR Immunotherapy Targeted to Melanoma. We have successfully achieved the milestones laid out in our initial application. We generated a lentiviral gene vector capable of expressing a T cell receptor (TCR) specific for the tyrosinase:368-376 epitope, and demonstrated the act ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Solving the MRI motion problem with Framewise Integrated Real-Time MRI Monitoring (FIRMM) software
SBC: TURING MEDICAL TECHNOLOGIES INC Topic: 101Project Abstract/Summary The goal of this SBIR/STTR application is to deliver a technology that accurately and non-invasively measures a patient’s head motion during a structural magnetic resonance imaging (MRI) scan (Framewise Integrated Real-Time MRI Monitoring -structural [FIRMM-s]). Because structural MRI scanning produces high-resolution images and does not expose patients to radiation, it ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
VGo-Assist, A Mobile Telepresence Robot to Engage Persons with Alzheimer's Disease and Related Dementias
SBC: VECNA TECHNOLOGIES, INC Topic: NIAProject Summary/Abstract Assistive Technologies (AT) is a broad area of activities to support physical health, well-being, social connectedness, and ability to live independently at home. Assistive Robotics (AR) has largely referred to robots that assisted people through physical interaction, while Socially Interactive Robotics (SIR) describe machines that interact primarily through social interac ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
ARPA-H-01 TOPIC: STREPAPP: DEEP LEARNING TO DIAGNOSE STREPTOCOCCAL PHARYNGITIS
SBC: AUSCULTECH DX LLC Topic: AH01This Phase II project is for the advancement of diagnostic capabilities for detecting Group A Streptococcus pharyngitis (GAS). The goals under the contract include a comprehensive and diverse database, multiple trained and optimized deep learning models deployable on a mobile device, FDA clearance for the algorithms, and the validation of the app's performance through clinical research. These achi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of VLP vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDRespiratory syncytial virus (RSV) is a significant human pathogen severely impacting neonates and young children, but no vaccine exists to protect this vulnerable population. Furthermore, direct vaccination of neonates is likely ineffective due to the immaturity of their immune system, and neonate immunization is potentially unsafe. The current view is that maternal vaccination is the best and saf ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales
SBC: REVERAGEN BIOPHARMA, INC. Topic: NINDSAbstract Vamorolone is a first-in-class dissociative steroidal drug that is being developed for Duchenne muscular dystrophy as a replacement for corticosteroid standard of care (prednisone, deflazacort) by small business ReveraGen BioPharma. ReveraGen completed first-in-patient studies with the aid of a NINDS SBIR Direct-to- Phase II award (48 DMD boys; sequential clinical trials VBP15-002, VBP15- ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine
SBC: PROFECTUS BIOSCIENCES, INC. Topic: NIAIDDESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a number of developed countries, the risk of death associated with HIV-1 infection has sharply declined due to the use of highly active antiretroviral therapy (HAART). Unfortunately, the rate of new HIV i ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Pivotal trial of vamorolone in Duchenne muscular dystrophy
SBC: REVERAGEN BIOPHARMA, INC. Topic: NINDSAbstract ReveraGen BioPharma is a clinical stage drug development company that is developing vamoroloneVBPa first in class dissociative steroidal drugThe initial indication being tested is Duchenne muscular dystrophyDMDwhere vamorolone holds promise for retaining or increasing efficacy of glucocorticoidswhile reducing adverse effectsbone fragilitystunting of growthweight gaininsulin resistanceReve ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health